Australian Doctor Australian Doctor 15th September 2017 | Page 20

NOW AVAILABLE
FREE ON THE
NATIONAL
IMMUNISATION
PROGRAM FOR 70-79
YEAR OLDS¹
HELP PROTECT YOUR 70-79 YEAR OLD
PATIENTS FROM SHINGLES AND PHN²
AVAILABLE FOR 70 YEAR OLDS, WITH A 5-YEAR CATCH UP
PROGRAM FOR 71 – 79 YEAR OLDS 1
PHN = Postherpetic Neuralgia
Hypothetical patient profile. May not be representative of every patient’s experience of shingles.
Before prescribing, please review the Product Information available at
www.seqirus.com.au/PI
MINIMUM PRODUCT INFORMATION: ZOSTAVAX® Zoster Virus Vaccine Live (Oka/Merck), Refrigerator stable Indications: Prevention of herpes zoster (shingles) in individuals 50 years of age and older. Prevention of postherpetic neuralgia (PHN) and reduction
of acute and chronic zoster-associated pain in individuals 60 years of age and older. * Contraindications: History of hypersensitivity to any component of the vaccine, including gelatin. History of anaphylactic/anaphylactoid reaction to neomycin. Primary and acquired
immunodeficiency states due to conditions such as: acute and chronic leukaemias; lymphoma; other conditions affecting the bone marrow or lymphatic system; immunosuppression due to HIV/AIDS; cellular immune deficiencies. Immunosuppressive therapy including
high-dose corticosteroids, but not topical/inhaled corticosteroids. ZOSTAVAX is a live, attenuated varicella-zoster vaccine and administration may result in disseminated disease in immunosuppressed or immunodeficient patients. Active untreated tuberculosis.
Pregnancy (see PRECAUTIONS). Precautions: Adequate treatment provisions, including adrenalin injection (1:1000), should be available for immediate use should an anaphylactic/anaphylactoid reaction occur. Consider deferral of vaccination in the presence of
fever >38.5°C. Safety and efficacy not established in adults known to be infected with HIV. Use in Pregnancy (Category B2): Do not administer to pregnant females; pregnancy should be avoided for 3 months after vaccination. Use in Lactation: It is not known
whether VZV is secreted in human milk. Use in the elderly: The mean age of subjects enrolled in the largest (N=38,546) clinical study of ZOSTAVAX was 69 years (range 59-99 years). ZOSTAVAX was demonstrated to be generally safe and effective in this population.
*Interactions with other medicines: ZOSTAVAX can be administered concurrently with inactivated influenza vaccine. ZOSTAVAX and PNEUMOVAX 23 should not be given concomitantly because concomitant use resulted in reduced immunogenicity of
ZOSTAVAX. Consider administration of the two vaccines separated by at least 4 weeks. Adverse Effects: headache, erythema, pain/tenderness, swelling, pruritus, fatigue, haematoma, warmth, induration, pain in extremity. Post-marketing experience:
varicella, zoster, nausea, arthralgia, myalgia, injection-site rash, injection-site urticaria, pyrexia, transient injection-site lymphadenopathy, hypersensitivity reactions including anaphylactic reactions, rash, necrotizing retinitis. Dosage and Administration:
A single dose (0.65mL) administered subcutaneously. Administer vaccine immediately after reconstitution to minimise loss of potency. ZOSTAVAX is not a treatment for zoster or PHN. Based on Approved Product Information dated 26 April 2016.
*Please see change(s) in Product Information
PBS Information:
This product is listed on the National Immunisation Program (NIP).
Refer to schedule.
References: 1. Department of Health. Australian Government Department of Health. National Immunisation Program Schedule. Available at: http://www.immunise.health.gov.au. 2. ZOSTAVAX® approved Product Information,
April 2016. Seqirus (Australia) Pty Ltd ABN: 66 120 398 067 63 Poplar Road, Parkville VIC 3052 www.seqirus.com.au; distributor for Merck, Sharp and Dohme (Australia) Pty Ltd. CSL Medical Information: 1800 642 865.
®ZOSTAVAX is a registered trademark of Merck & Co. Inc Whitehouse Station, NJ, USA. Seqirus TM is a trademark of Seqirus UK Limited or its affiliates.
Date of preparation October 2016. SEQ/ZOST/0816/0148c. 02071SEQ/AD/FP.